Cellular Senescence

A stable, heritable cell-cycle arrest (canonically durable but conditionally reversible — see senescence-escape) triggered by DNA damage, telomere erosion, oncogene activation, or metabolic stress — accompanied by morphological remodeling, the Senescence-Associated Secretory Phenotype (SASP), and upregulation of pro-survival BCL-2 family members that resist apoptosis. One of three Antagonistic hallmarks in López-Otín et al. 2013 and 2023: evolutionarily adaptive in youth (tumor suppression, wound repair, developmental patterning) but damaging when senescent cells accumulate chronically in aged tissues, driving inflammaging, tissue dysfunction, and paradoxically a pro-tumor microenvironment.

Definition (López-Otín 2013, retained 2023)

Cellular senescence is stable cell-cycle exit characterized by:

SA-β-gal positivity — lysosomal β-galactosidase activity detectable at pH 6.0 (established by Dimri 1995 ¹; verified on p21)
p16INK4a and/or p21CIP1 induction — two partially overlapping CDK inhibitor checkpoints that enforce and reinforce arrest; see p21 (verified-partial) and p16-rb-pathway (planned)
SASP — constitutive secretion of cytokines (IL-6, IL-8), chemokines (CCL2, CXCL1), MMPs, and growth factors; see sasp (verified)
Resistance to apoptosis — upregulation of BCL-2 family pro-survival members (cell-type-specific SCAPs); see bcl-2-family-signaling (verified-partial)
Morphological change — flattened, vacuolated cell body; enlarged nucleus; heterochromatin foci (SAHF)

Senescent cells accumulate in virtually every aged tissue. Experimental clearance via genetic systems (INK-ATTAC, p16-3MR) or pharmacological senolytics extends healthspan and lifespan in mice and reduces senescent-cell burden in humans ²³.

Direct human cross-sectional accumulation evidence. Beyond intervention studies, age-stratified surveys of human tissue confirm marker accumulation directly. Idda et al. 2020 measured p16^INK4a^ and p21^CIP1^ by immunohistochemistry across 10 organs in young (13–35), middle-aged (40–59), and old (>65) human donors (n=5/group): both markers rose with age in a tissue-specific, non-uniform pattern — p16 reaching ~35% of cells in elderly endocrine pancreas (the largest burden), with smaller age-related rises in liver, intestine, spleen, brain cortex, kidney, and skin epidermis; skin dermis showed a p21-selective rise; lung showed no change and skeletal/cardiac muscle had no detectable signal ⁴. A systematic review of 103 studies (9 organ systems, 27 age-related diseases) found elevated senescence-marker expression consistently associated with human age-related disease tissue, with p16^INK4a^ the most-used marker (23 of 27 pathologies), though it flagged a pervasive lack of marker standardization across the literature ⁵. These build on the two foundational biomarker anchors: Krishnamurthy 2004 first established that p16^INK4a^/Ink4a-Arf expression rises ~10-fold across aged rodent tissues and tracks biological (not merely chronological) age — caloric restriction blunts the rise ⁶ — and Ressler 2006 validated p16^INK4a^ as a robust in vivo marker of cellular aging in human skin biopsies ⁷. Together they converge with the SenNet consensus below: human senescence is real and accumulates with age, but is heterogeneous and poorly served by any single marker.

Detecting senescent cells in tissue (SenNet 2024 consensus): because no single marker is specific and senescent cells are rare in vivo, the SenNet Biomarkers Working Group recommends tissue-specific multi-marker panels — combining molecular senescence signatures, morphological features, and circulating markers — for detecting senescent cells, based on a literature analysis across 14 mouse/human tissues ⁸. A curated 703-entry biomarker table (marker × tissue × cell × context × organism × hallmark, each with a PMID) accompanies it — snapshot at sennet-biomarkers.

A reagent-level confound compounds the standardization gap (2026). Beyond the “no universal marker” problem, the most-used marker — p16INK4a by immunohistochemistry — has a widespread antibody-specificity failure: a 2026 research-integrity analysis (S. David) found that across the senescence literature, the large majority of papers using certain catalog antibodies were detecting the unrelated actin-cytoskeleton protein p16-ARC (ARPC5), not p16INK4a. This down-weights much of the correlative p16-IHC accumulation literature, while leaving the antibody-independent evidence intact — genetic reporters (INK-ATTAC, p16-3MR), Cdkn2a qPCR (e.g. ⁶), and transcriptomic signatures. See p16-immunodetection for the methodological detail and evidence-weight rules. gap/needs-replication (David analysis not yet peer-reviewed).

SENS correspondence: ApoptoSENS — the senescent cell type that should be removed by targeted induction of apoptosis. Senolytics implement this strategy pharmacologically.

Discovery: the Hayflick limit and modern senescence biology

The Hayflick limit (1961) established that normal human diploid fibroblasts undergo a fixed number of population doublings (~50) before entering permanent growth arrest — replicative senescence. Subsequent decades established that senescence is not merely a culture artifact but a regulated cellular program triggered by multiple distinct stimuli, with profound organismal consequences.

The modern view integrates several insights not available in 1961:

Senescence can be triggered without telomere exhaustion (oncogene-induced, stress-induced, metabolic)
Senescent cells persist in vivo and accumulate with age
The SASP is the dominant aging-relevant output of senescent cells — not the arrest itself
Cell-type-specific anti-apoptotic programs (SCAPs) are pharmacologically exploitable

For the molecular basis of replicative senescence (telomere-driven DDR): see telomere-attrition (drafted, synthesis-MOC) and dna-damage-response (verified-partial).

Triggers of senescence

1. DNA damage / replicative senescence

Telomere shortening with each division eventually generates uncapped telomere ends recognized as persistent DNA double-strand breaks — Telomere-Associated DDR Foci (TAFs). Persistent unresolved DDR foci (PDDFs at ≥10 Gy doses; not at 0.5 Gy per Rodier 2009 dose-response) activate the dna-damage-response pathway (verified-partial), which bifurcates into two separable arms ⁹:

Growth-arrest arm — ATM → CHK2 → p53 → p21 (CDK inhibition → Rb hypophosphorylation → E2F arrest)
SASP arm — ATM / NBS1 / CHK2-dependent but p53-INDEPENDENT IL-6 and IL-8 secretion (ATM depletion reduces IL-6 ~50-fold, IL-8 ~10-fold per atm (verified-partial)); nine other SASP factors are ATM-independent

This two-arm architecture has fundamental therapeutic implications: inhibiting p53 does not suppress the inflammatory SASP arm, and a cell can acquire pro-inflammatory secretory activity without full growth arrest.

2. Oncogene-induced senescence (OIS)

Activation of oncogenes (RAS, BRAF^V600E^, MYC) triggers the ARF pathway, which sequesters MDM2, stabilizing p53 and inducing senescence as an anti-tumor barrier (see mdm2 (verified-partial)). OIS is critical in the context of premalignant lesions — tumor-infiltrating senescent cells are often early OIS cells that have restrained clonal expansion. The sasp (verified) in OIS context is regulated by C/EBPβ as well as NF-κB — see nf-kb (verified-partial).

3. Stress-induced premature senescence (SIPS)

Oxidative stress, metabolic stress (hyperglycemia, lipotoxicity), mitochondrial dysfunction, and chemotherapy/radiation all induce senescence via DNA damage and/or p38-MAPK → p16INK4a pathways without obligate telomere shortening. Particularly relevant to tissue aging where oxidative stress is chronic but replicative exhaustion has not occurred.

4. Developmental / transient senescence

Senescence is not exclusively pathological. In embryogenesis, transient senescent cells pattern the placenta and limbs; in wound healing, senescent myofibroblasts promote scar resolution via PDGF-AA secretion and are then efficiently cleared by NK cells (canonical mechanism: senescence-immune-surveillance). This good senescence (clearance-dependent, beneficial) is mechanistically similar to chronic aging-associated accumulation — the critical difference is efficient immune-mediated clearance, which declines with age (#gap/no-mechanism — the switch between resolved developmental vs persisting age-related senescence is not fully characterized at the molecular level).

5. Mitochondrial dysfunction-induced senescence (MiDAS)

Mitochondrial dysfunction can induce senescence without DNA damage, via ROS-driven mTORC1 activation and NAD^+^/NADH imbalance. The SASP in MiDAS is distinct — high IL-1α, low metalloproteinase content; see sasp (verified) § MiDAS variant (MIDAS).

6. Mitochondrial RNA leakage as DAMP-driven SASP amplifier

A mechanistically distinct mitochondrial-senescence axis (Victorelli 2025, López-Polo 2024, Zhang 2026 — 3-lab convergence across MASH and cognitive-aging contexts) shows that cytosolic mt-dsRNA leaked via BAX/BAK miMOMP or SEC61A1-mediated permeability activates RIG-I/MDA5 → mavs → TBK1/IKKε → IRF3/IRF7 + NF-κB → SASP amplification. The arm operates in parallel to the cytosolic mtDNA → cgas-sting axis and provides a direct mechanistic bridge from the mitochondrial-dysfunction hallmark to cellular senescence. Distinct from MiDAS (metabolic AMPK→p53 arm; section 5 above) — the mtRNA arm is innate-immune DAMP-sensing. Full integration, intervention landscape (shared TBK1/IKKε handle via amlexanox), and 3-lab data on mitochondrial-rna-leakage.

Senescent-cell heterogeneity and the senotype concept

Senescent cells are not a single uniform state. Prior wiki content already documents cell-type-specific SASP composition (see sasp § SASP composition — e.g. astrocyte SASP is complement-enriched, fibroblast SASP is MMP-enriched; the senescent-cardiomyocyte non-canonical SASP is documented on cardiac-fibrosis) and cell-type-specific anti-apoptotic programs (SCAPs — see § Anti-apoptotic programs (SCAPs) above, and senolytics for the full SCAP map). A 2026 Perspective from the NIH SenNet (Cellular Senescence Network) Consortium formalizes and extends this observation into a systematic framework ¹⁰.

The senotype concept: Suryadevara et al. 2026 propose that senescent cells in vivo comprise heterogeneous, tissue-specific cell states — termed “senotypes” — shaped by both cell identity and microenvironmental context within a given tissue. This goes beyond the cell-type-specific SASP / SCAP distinctions characterized in vitro: the senotype framework claims that even within a single tissue, the microenvironment (neighboring cells, ECM signals, inflammatory milieu) shapes the senescent state in ways that are only resolvable by single-cell and spatial methods.

Enabling methodology: The Perspective argues that integrating single-cell multi-omics, spatial multi-omics, and AI-driven analyses is necessary to map senotype heterogeneity systematically across human tissues — conventional bulk-tissue markers (p16^INK4a^, SA-β-gal, composite SASP panels) capture overlapping but incomplete subsets of the full senescent-cell population and do not resolve tissue-specific programs. This methodological claim extends the existing biomarker gap (#gap/no-mechanism — no universal clinically usable senescent-cell biomarker) to note that the heterogeneity is itself a structural explanation for why single-marker approaches are insufficient.

Therapeutic implication: The senotype framework motivates senotype-targeted senotherapeutic strategies rather than pan-senolytic approaches. This parallels the existing SCAP-matching principle (no single senolytic is pan-effective; cell-type composition of the target tissue determines which agent to use), but extends it to include spatial microenvironmental context and implies that future senolytic / senomorphic development should incorporate tissue-specific senotype profiling.

Emerging modality — transcript-addressed killing: A programmable cell-ablation approach (transcript-activated-cell-ablation) could in principle operationalize senotype-targeting by programming an RNA-guided nuclease (Cas12a2) to a senotype-specific trigger transcript — killing by RNA identity rather than by the anti-apoptotic dependency that small-molecule senolytics exploit (Doudna lab, cancer-only proof of concept, Nature 2026 — zeng-2026-cas12a2-chromatin-shredding). The catch is that the same no-universal-marker heterogeneity that motivates senotype-targeting is also the obstacle: there is no senescence-exclusive trigger transcript (p16^INK4a^/CDKN2A is not senescence-specific), so a transcript-addressed killer for senescence is hypothesis, not result. gap/no-mechanism

Scope caveat: This framework is introduced in a Perspective article. Two companion SenNet data papers are now seeded — the SenCat multi-omic senescence catalog (anerillas-2026-sencat, Molecular Cell) and the lymph-node immunosenescence spatial atlas (farzad-2026-immunosenescence-atlas). Others remain future seeding leads (a broader cross-tissue atlas; blood senescence biomarkers predicting kidney disease / frailty / diabetes; the SenLect purification tool). See suryadevara-2026-senotypes for details. gap/needs-replication (senotype concept introduced in one Perspective; independent validation of the framework and specific senotype identities awaits primary atlas data and replication).

Empirical support from companion data papers (2025–2026): Several companion papers supply data consistent with the tissue-specificity and functional-heterogeneity predictions of the senotype framework — one peer-reviewed SenNet consortium data paper (SenCat) plus two independent Krizhanovsky-lab (Weizmann) preprints (the preprints are not SenNet papers — independent corroboration from a separate group).

No universal marker; a shared repair core; an ML signature (SenCat, Anerillas 2026 — peer-reviewed SenNet) ¹¹: The SenNet SenCat catalog profiled transcriptomes + proteomes of 14 primary human cell types across >30 senescence paradigms (Molecular Cell). Senescent cells share no single universal marker (catalog-scale confirmation that single-marker detection is insufficient — the empirical core of the senotype concept), yet all activate shared metabolic and damage-response pathways implicated in tissue repair; ML-refined SenCat signatures score senescence across human and mouse bulk and single-cell datasets. This is the strongest peer-reviewed support for senotype heterogeneity and supplies a composite signature where single markers fail.
Organ-level coordination and uncoupling (Cherqui 2025) ¹²: Applying a novel single-cell, protein-level multi-marker approach across multiple mouse tissues and human PBMCs, Cherqui et al. 2025 (preprint) find that senescence accumulation is strongly coordinated within organs but shows little correlation across organs — supporting the idea of a tissue-specific progression of aging. This provides quantitative empirical grounding for the tissue-specificity arm of the senotype concept: the cellular aging clock runs differently in different organs, rather than progressing as a synchronized systemic process. gap/preprint-not-peer-reviewed
csV1B2-marked apoptosis-resistant subset (Freizus 2025) ¹³: Freizus et al. 2025 (preprint) identify a subset of senescent cells that upregulates atp6v1b2 (V-type ATPase subunit B2) on the cell surface (csV1B2) following DNA-damage-induced senescence. This subset carries a transcriptional signature associated with DNA repair and apoptosis resistance, is present in aging and fibrotic lungs in vivo, and shows resistance to ABT-737-induced apoptosis in culture — a functional correlate of senolytic evasion within the BH3-mimetic drug class. This is a concrete functional senotype with direct therapeutic-resistance implications; see senolytics for the BH3-mimetic class context. gap/preprint-not-peer-reviewed

Two arms of intervention: production rate and clearance

Senescent-cell burden = production rate × residence time. The age-related uptick reflects both arms degrading: triggers accumulate (telomere attrition, oxidative damage, NAD⁺ decline, mitochondrial dysfunction, hyperglycemia) and immune clearance fails (NK-cell and macrophage senescent-cell removal declines with age; see immunosenescence). Both arms are addressable, and the two strategies are complementary rather than substitutive.

Production-rate reduction acts upstream — interventions on the hallmarks listed in caused-by: (genomic-instability, telomere-attrition, epigenetic-alterations, mitochondrial-dysfunction, deregulated-nutrient-sensing). Examples include rapamycin / mTORC1 inhibition, caloric-restriction and time-restricted eating, NAD⁺ precursors (nmn, nr), GLP-1 agonists addressing hyperglycemia, mitophagy enhancers (urolithin-a, spermidine). These slow new senescent-cell formation but do not remove cells that have already entered stable arrest.

Residence-time reduction acts downstream — senolytic clearance of accumulated cells, or improving the immune-surveillance arm (thymic regeneration, NK-cell function preservation — both preclinical or single-trial). Senolytics are unique in addressing already-accumulated cells; every other geroscience intervention works on the production-rate side.

The marginal benefit of each arm shifts with age: at lower accumulated burden (mid-life), upstream prevention has higher lifetime AUC; at higher burden (late life), clearance has larger marginal effect. See interventions-by-hallmark for the full intervention-class matrix and hallmark-causality-graph § Implications for intervention sequencing for the tier-based prioritization argument.

This production-vs-clearance split is the biological substrate of the Saturating Removal model, in which senescent cells are the leading candidate for the model’s scalar “damage” variable. The model’s origin paper (Karin & Alon 2019) measured senescent-cell turnover in mice and found the per-cell clearance half-life lengthens ~5-fold with age (~5 days at 3 mo → ~25 days at 22 mo) ¹⁴. Crucially, the model reproduces this slowdown via density-dependent self-inhibition — clearance is a saturating (Michaelis–Menten) process, so the per-cell removal rate β/(κ+X) falls as senescent burden X rises, a positive feedback (“critical slowing down”). This is mechanistically distinct from the age-related immune decline described above: Karin & Alon found extrinsic immune aging was not required to fit the turnover data — abundance-driven saturation of a fixed-capacity clearance suffices. (Both can contribute in reality; the point is the SR accumulation is intrinsic, not contingent on immunosenescence.) At the demographic scale, the 2026 cross-species extension reaches a pointed conclusion: across nine species, the damage-production rate (η — the upstream arm) is the single best predictor of lifespan and the parameter evolution actually tunes, whereas removal (β) is nearly invariant across mammals ¹⁵. The catch: reducing production alone stretches sickspan as well as lifespan — compressing morbidity requires also raising the death threshold or reducing biological noise, not production-lowering alone. See raz-2026-sr-model-aging-regimes.

Core molecular machinery

p53/p21 growth-arrest axis

p53 (TP53, p53 — verified) is stabilized by DNA damage (via ATM-mediated Ser15 phosphorylation), oncogene activation (via ARF/MDM2), and other stressors. Active p53 transcribes p21 (CDKN1A — verified-partial), which inhibits CDK2/cyclin-E to prevent G1→S transition. This is the canonical senescence initiation checkpoint.

Key aging evidence:

Baker 2016 ²: Chronic clearance of p16^Ink4a^-positive cells in naturally aged mice (INK-ATTAC transgene, AP20187 treatment from 12 months, twice weekly) extended median lifespan 27% in 129Sv×C57BL/6J×FVB mixed background and 24% in congenic C57BL/6J; range 17–35% by sex and background. Tumor incidence was not reduced at autopsy (latency increased). Full verification: see p21 (verified), senolytics (verified-partial).
p21 deletion in late-generation Terc^−/−^ mice with dysfunctional telomeres partially rescues stem-cell proliferative capacity and extends lifespan in that model, establishing a causal role for p21-mediated arrest in telomere-damage-driven tissue aging — see p21 (verified).

p16INK4a/Rb axis — reinforcement layer

p16INK4a (CDKN2A product) inhibits CDK4/6 → prevents Rb phosphorylation → independently reinforces the growth-arrest checkpoint. p16INK4a expression increases exponentially with age in most tissues; it is the most widely used in vivo senescent-cell biomarker and the driver of the INK-ATTAC transgene strategy. For detailed pathway logic: see p16-rb-pathway (verified-partial).

SASP: the secretory output

The SASP is the aging-relevant output of senescent cells — a complex inflammatory secretome whose core includes IL-6, IL-8, IL-1α, CCL2, CXCL1, and MMP-3. Canonical regulation: NF-κB is the master transcription factor; the IL-1α/IL-1R autocrine loop locks NF-κB in the “on” state; GATA4 escapes autophagy in senescent cells and activates NF-κB; cGAS-STING senses cytoplasmic chromatin fragments and feeds IKK → NF-κB; mTORC1 provides the translational amplification. For full composition and regulation: see sasp (verified).

Two-arm SASP model (Rodier 2009, verified on dna-damage-response): The growth-arrest arm (p53/p21) and the inflammatory SASP arm (ATM/NBS1/CHK2) are separable — NF-κB-driven SASP is p53-independent. This means a cell can acquire SASP secretory activity without full arrest, and p53 rescue does not suppress SASP. See atm (verified-partial) for the IL-6/IL-8 dose-response.

Cell-type-specific SASP variants:

Cardiomyocytes: Non-canonical SASP (TGFβ2, GDF15, EDN3 — no canonical IL-6/IL-8 in purified cardiomyocyte fraction per Anderson 2019) — see cardiomyocytes (verified)
Astrocytes: Complement-enriched; see microglia (verified-partial — DAM populations)
Fibroblasts (IMR90): MMP-dominant; canonical inflammatory core

Anti-apoptotic programs (SCAPs)

Senescent cells resist apoptosis by upregulating pro-survival pathways — the Senescent-Cell Anti-Apoptotic Pathways (SCAPs). SCAPs are highly cell-type-specific and this heterogeneity defines the cell-type-matching challenge for senolytics. Full SCAP map with compound sensitivities: senolytics (verified-partial).

Cell-type SCAP summary:

Cell type	Primary SCAP nodes	Effective senolytics
HUVECs (endothelial)	BCL-xL, EFNB1	quercetin, navitoclax, A-1331852
IMR90 fibroblasts	BCL-2 + BCL-xL + BCL-W triple (required; no single sufficient)	navitoclax, A-1331852; quercetin partial
Human preadipocytes	Ephrins (EFNB1/3); EPH receptors; PI3Kδ; p21; PAI-2	dasatinib (D); D+Q combination
Cardiomyocytes	BCL-xL + non-canonical SASP	navitoclax (in vivo — Anderson 2019)

FOXO4-p53 axis in senescent survival: In senescent cells, FOXO4 protein levels are selectively elevated and FOXO4 sequesters p53 in a nuclear complex, preventing pro-apoptotic p53 translocation to mitochondria. The FOXO4-DRI peptide (Baar 2017) disrupts this interaction, releases p53 to cytoplasm, and triggers caspase-3/7-dependent apoptosis selectively in senescent cells ¹⁶ — see foxo4 (verified). This is the canonical proof-of-concept for protein-protein interaction senolytics.

Genetic proof: lifespan extension by senescent-cell clearance

Baker et al. 2016 (Nature) is the landmark demonstration that chronic senescent-cell accumulation causally limits healthspan and lifespan in wild-type aging mice ²:

Model: INK-ATTAC (p16Ink4a promoter → caspase 8 dimerization + GFP reporter); AP20187 administered twice weekly from 12 months of age
Lifespan: +27% median (mixed background), +24% (congenic C57BL/6J); range 17–35%
Healthspan phenotypes improved: Kidney function, adipose tissue function, cardiac stress tolerance, tumor-free survival curves
Cancer: Tumor incidence at autopsy NOT reduced (latency increased, but senescent-cell accumulation does not eliminate cancer risk — consistent with the aging-cancer paradox below)
Caveats: All results are mouse studies; BubR1 progeroid model (Baker 2011) vs wild-type aging (Baker 2016) — the wild-type result is more directly translatable; p16Ink4a+ cells are not all senescent, and not all senescent cells are p16+

Full Baker 2016 numeric verification: p21 (verified) and senolytics (verified-partial).

Senolytic intervention paradigm

The senolytic drug class targets SCAPs to selectively kill senescent cells. See senolytics (verified-partial) for the full class description, SCAP framework, and compound summaries. Key compounds:

Dasatinib + Quercetin (D+Q) — the canonical combination ¹⁷:

Dasatinib (tyrosine kinase inhibitor; ephrin/EPH targets in preadipocytes): dasatinib (verified)
Quercetin (BCL-xL / EFNB1 in HUVECs): quercetin (verified-partial)
Neither alone is a pan-senolytic; combination covers complementary cell-type populations
Justice 2019 (IPF pilot, open-label, n=14): D+Q for 3 weeks (Q 1,250 mg/day; 3 consecutive days/week × 3 weeks = 9 dosing days); 6-minute walk distance +21.5 m (p=0.012), gait speed +0.12 m/s (p=0.024), chair-stands −2.2 s (p=0.013); pulmonary function NS ¹⁸
Hickson 2019 (DKD pilot, open-label, n=9): D+Q for 3 consecutive days (single course; Q 1,000 mg/day in 2 divided doses); p16INK4A+ cells −35% (p=0.001), p21CIP1+ cells −17% (p=0.009), SA-β-Gal+ cells −62% (p=0.005) in abdominal subcutaneous adipose tissue biopsies at Day 14 — all three measured by IHC/immunohistochemistry cell counting (% positive cells per 100 adipocytes or per nucleus), NOT mRNA; skin epidermis showed separately-quantified reductions: p16INK4A+ cells −20% (p=0.026), p21CIP1+ cells −31% (p=0.016), both significant; senescent cell burden reduction confirmed in humans ³

Fisetin — broad senolytic; fisetin (verified):

Yousefzadeh 2018: ~50% reduction in p16^+^c-Kit^+^ cells in aged mice; median healthspan extension
Cell-type selective — senolytic in HUVECs (apoptosis), senomorphic in MEFs (marker reduction without killing); NOT a BCL-2 family inhibitor
Phase 2 trials ongoing as of 2026

Navitoclax (ABT-263) — BCL-2/BCL-xL/BCL-W pan-inhibitor; navitoclax (planned):

IMR90 and HUVEC senolysis confirmed (Zhu 2016, Zhu 2017)
Preadipocyte senolysis: null (not covered by navitoclax SCAP)
Clinical concern: thrombocytopenia (BCL-xL platelet dependency) limits dose and duration
PROTAC degraders (DT2216, PZ15227) targeting BCL-xL with E3-ligase recruitment to spare platelets are in preclinical development gap/needs-human-replication

A-1331852 — selective BCL-xL inhibitor; a1331852 (verified-partial):

Higher senolytic potency vs navitoclax in HUVEC model
Narrower SCAP coverage; preclinical only

UBX1325 / foselutoclax — first positive BCL-xL-axis senolytic Phase 2 in humans (2025). Klier et al. NEJM Evidence 2025 reported the BEHOLD Phase 2 RCT (n=65) of intravitreal UBX1325 in diabetic macular edema: +5.6 ETDRS letters vs sham at the primary timepoint. This is the first clinical-stage positive primary endpoint for the BCL-xL-axis senolytic class (vs the D+Q combination, which has positive open-label data but a negative placebo-controlled bone-loss trial — see Farr 2024 below). Local intravitreal delivery sidesteps the systemic-thrombocytopenia constraint that blocks navitoclax aging deployment. See senolytics for class-level pipeline updates.

Updated D+Q evidence (2024–2026). Farr 2024 Nat Med (n=60 postmenopausal, NCT04313634) — the first placebo-controlled D+Q RCT — missed the primary endpoint (CTx Δ p=0.611). Exploratory subgroup analyses by T-cell-p16 tertile showed responders (high-p16 group: radius BMD +2.7%); a biomarker-stratified follow-up (Farr 2025 Aging Cell) is in progress. Liu 2025 Nat Med COIS-01 (n=51 HNSCC + anti-PD-1) reported 33.3% major pathological response — the first independent (non-Mayo) D+Q clinical evidence, but in immunotherapy-adjunct framing, not aging. Emerging regimen-specific safety signal: Lombardo 2026 PNAS found nonlethal oligodendrocyte dysfunction and rostral corpus-callosum demyelination after D+Q in healthy mice ¹⁹. The study did not measure brain senescent-cell burden or target engagement, so it does not show that senolysis caused the injury or negate benefits of selective senescent-cell clearance; the UPR mechanism also remains associative. gap/needs-replication gap/needs-human-replication.

FOXO4-DRI peptide ¹⁶:

Designed as cell-permeable D-amino acid retroinverso peptide spanning FOXO4 residues 86–206
Disrupts FOXO4-p53 interaction → cytosolic p53 release → caspase-3/7-mediated selective apoptosis of senescent cells
In vivo: improved kidney function (plasma urea), fur density score, physical responsiveness, running wheel activity in XpdTTD/TTD fast-aging mice and naturally aged mice
Proof-of-concept for PPI-targeted senolytics; not in clinical development as of 2026

Senomorphic intervention paradigm

Where senolytics kill senescent cells, senomorphics suppress the SASP without cell killing. See senomorphics (verified-partial) for the class description.

Key senomorphic mechanisms:

JAK1/2 inhibition (momelotinib, ruxolitinib) — suppresses JAK-STAT-mediated SASP cytokine production; Xu 2015 ²⁰: JAK1/2 inhibition reduced IL-6 secretion and improved physical function in aged mice — see senomorphics (verified-partial)
mTORC1 inhibition (rapamycin, RAD001) — attenuates SASP at the translational level via 4E-BP1; see mtor (verified-partial)
NF-κB inhibition (various) — suppresses the master SASP transcriptional regulator; see nf-kb (verified-partial)
IL-1 neutralization (canakinumab/CANTOS) — IL-1β antibody reduced MACE HR 0.85 (95% CI 0.74–0.98, p=0.021) in a cardiovascular outcome trial — see atherosclerosis (verified); however CANTOS was not designed specifically as a senomorphic trial

Senomorphic vs senolytic trade-off: Senomorphics may be preferable where senescent cells serve structural roles (fibroblasts in wound beds, transient developmental senescence); senolytics are preferable where chronic SASP accumulation dominates. The two strategies are not mutually exclusive.

Aging-cancer paradox

Senescence is an archetypical example of antagonistic pleiotropy in aging biology:

Young: Senescence suppresses tumorigenesis by arresting damaged cells before malignant transformation; OIS arrests pre-malignant RAS-activated cells; developmental senescence patterns embryonic tissues transiently. Anti-tumor function is beneficial. Efficient immune clearance of senescent cells by NK cells and macrophages (via SASP-mediated “find me / eat me” signals; see senescence-immune-surveillance) prevents accumulation.

Old: Chronic senescent cell accumulation with declining immune surveillance produces a pro-tumor stromal microenvironment via SASP-mediated ECM remodeling, angiogenic factor secretion (VEGF), and paracrine growth-factor signaling. Baker 2016 INK-ATTAC clearance increased tumor latency but did NOT eliminate tumor incidence at autopsy — consistent with senescence being one node in the pro-tumor milieu, not the only driver ². See cancer (verified) for full paradox treatment including Tyner 2002 (p53 hyperactivation → tumor resistance + 23% shorter lifespan) and Pten-elevation longevity data.

Senescence-mediated paracrine spreading: SASP factors promote bystander senescence in neighboring cells (sasp — verified § paracrine senescence), amplifying the senescent cell burden beyond the initial insult — a feed-forward mechanism accelerating tissue aging.

Disease phenotype cluster

This hallmark has the widest verified disease-connection cluster in the wiki. Each link references the verified atomic page for quantitative detail:

Disease	Senescence mechanism	Evidence level	Page
atherosclerosis	Senescent VSMCs + endothelial cells → SASP-driven plaque instability; Childs 2016: ~60% plaque reduction with INK-ATTAC clearance in LDLR^-/-^ mice	Preclinical causal; human: observational	(verified-partial — Childs 2016 not_oa)
heart-failure	Cardiomyocyte senescence (Anderson 2019 non-canonical SASP TGFβ2/GDF15/EDN3); navitoclax reduced CM hypertrophy + fibrosis (EF unchanged, NS)	Preclinical; limited human	(verified)
cardiac-fibrosis	Fibroblast senescence → SASP-driven fibroblast-to-myofibroblast paracrine; TGFβ signaling	Preclinical	(verified-partial)
type-2-diabetes	β-cell senescence (Aguayo-Mazzucato 2019) → impaired insulin secretion; high p21 in T2D pancreas; SASP-driven islet inflammation	Preclinical + some human	(verified — Aguayo claim unverified against full PDF; flagged gap/no-fulltext-access)
frailty	Senescent satellite cells → impaired muscle regeneration; SASP-driven systemic inflammaging	Epidemiological + preclinical	(verified)
osteoarthritis	Senescent chondrocytes → cartilage-destructive SASP (MMP-13, IL-6); GDF15 from senescent cells	Preclinical; limited human	osteoarthritis (planned) gap/unsourced
neurodegeneration	Senescent microglia (DAM-like populations), astrocyte SASP → neurotoxic environment	Preclinical; limited human	microglia (verified-partial)
cancer	Paradox — see above	Preclinical causal; human: CHIP→cancer	(verified)

Clinical translation

Human senescent-cell burden evidence

Hickson 2019 (n=9 DKD patients, D+Q single 3-day course) is the first clinical demonstration that a pharmacological intervention reduces senescent-cell burden in human tissue: p16INK4A+ cells −35% (p=0.001), p21CIP1+ cells −17% (p=0.009), SA-β-Gal+ cells −62% (p=0.005) in abdominal subcutaneous adipose biopsies at Day 14 — all measured by IHC cell counting (% positive cells per 100 adipocytes or per nucleus), not mRNA; skin epidermis separately quantified: p16INK4A+ cells −20% (p=0.026), p21CIP1+ cells −31% (p=0.016); macrophages (CD68+) −28% (p<0.0001) and circulating SASP factors (IL-1α, IL-6, MMP-9/-12) also reduced ³. This establishes proof-of-target-engagement in humans; functional endpoints require larger trials.

Active human trials (as of 2026)

Justice 2019 — D+Q in IPF (n=14; open-label pilot); physical function endpoints showed improvement ¹⁸
Multiple Phase 2 trials ongoing for senolytics in frailty, diabetes, Alzheimer’s disease, osteoporosis, and IPF (NCT tracking deferred to ClinicalTrials.gov search)
Fisetin Phase 2 (Mayo Clinic) — frailty and physical function primary endpoints; ongoing

Translation caveats

All lifespan-extension data are murine; no human longevity data for any senolytic
SCAP cell-type specificity means no pan-senolytic exists — human tissue cell-type distribution at different disease stages determines which agent to use
Senolytic window of activity: senescent cells take days–weeks to repopulate after clearance; intermittent “hit-and-run” dosing may be optimal — confirmed for D+Q in Zhu 2015 ¹⁷
Long-term safety of chronic senolytic use unknown gap/long-term-unknown
Navitoclax thrombocytopenia risk limits deployment outside oncology settings

Targeted interventions

TABLE WITHOUT ID file.link AS Compound, mechanisms AS Mechanism, clinical-stage AS Stage, human-evidence-level AS "Evidence", translation-gap AS "Gap"
FROM "molecules/compounds" OR "interventions"
WHERE contains(hallmarks, [[cellular-senescence]])
  OR contains(target-hallmarks, [[cellular-senescence]])
SORT clinical-stage DESC

See interventions-by-hallmark for the full matrix, class-level synthesis, and gaps. See senolytics and senomorphics for class-level descriptions.

Cross-references

Processes:

sasp (verified) — the secretory phenotype that is the primary aging output of senescent cells
apoptosis (verified-partial) — the effector program senolytics engage to kill senescent cells
dna-damage-response (verified-partial) — the upstream trigger; two-arm SASP model

Pathways:

p53-pathway (verified-partial) — growth-arrest initiation
apoptosis-pathway (verified-partial) — SCAP context; BCL-2 family regulation
bcl-2-family-signaling (verified-partial) — SCAP molecular architecture; three-tier model
nf-kb (verified-partial) — master SASP transcriptional driver
p16-rb-pathway (verified-partial) — secondary reinforcement of growth arrest; p16/CDK4/6/RB/E2F axis; genetic ablation studies; INK-ATTAC system

Proteins:

p53 (verified) — tumor suppressor; FOXO4-sequestered in senescent cells; antagonistic pleiotropy
p21 (verified-partial) — growth-arrest arm effector; Baker 2016 clearance evidence
atm (verified-partial) — SASP induction (IL-6 ~50× / IL-8 ~10× ATM-dependent); two-arm model
foxo4 (verified) — FOXO4-p53 survival interaction; FOXO4-DRI proof-of-concept
mdm2 (verified-partial) — MDM2-p53 axis; Mendrysa 2006 inversion
bcl-xl (verified-partial), bcl-2 (verified-partial), bcl-w (planned) — SCAP anti-apoptotic nodes
mcl-1 (verified-partial) — BCL-2 family anti-apoptotic; not a primary SCAP in most senescent populations
bak (verified, FULL), bax (verified-partial) — effector pore-forming proteins
bim (verified-partial), puma (verified-partial), noxa (verified-partial) — BH3-only sensitizers / activators

Compounds:

dasatinib (verified) — D+Q “D”; preadipocyte ephrin/EPH SCAP
quercetin (verified-partial) — D+Q “Q”; HUVEC BCL-xL/EFNB1 SCAP
fisetin (verified) — Yousefzadeh 2018; PI3K/AKT/mTOR SCAP; broad spectrum in vivo
navitoclax (planned) — BCL-2/BCL-xL/BCL-W; IMR90 + HUVEC senolytic; thrombocytopenia-limited
a1331852 (verified-partial) — selective BCL-xL; HUVEC-active

Interventions:

senolytics (verified-partial) — SCAP framework; drug class overview; human trial summary
senomorphics (verified-partial) — SASP suppression; JAK/mTOR/NF-κB pathways

Cell types:

cardiomyocytes (verified) — non-canonical SASP; BCL-xL SCAP; Anderson 2019
satellite-cells (verified-partial) — muscle regeneration failure in aging; senescence involvement
microglia (verified-partial) — DAM phenotype; neuroinflammation
hematopoietic-stem-cells (verified-partial) — CHIP overlap; senescent-HSC contribution to immunosenescence

Phenotypes:

atherosclerosis (verified-partial) — Childs 2016 senolysis ~60% plaque reduction in mouse
heart-failure (verified) — Anderson 2019 CM non-canonical SASP
type-2-diabetes (verified) — β-cell senescence; Aguayo-Mazzucato 2019
frailty (verified) — chronic senescence → inflammaging → frailty convergence
cancer (verified) — aging-cancer paradox; SASP-driven pro-tumor stroma

Hallmarks:

genomic-instability — DDR is the proximal trigger for replicative and damage-induced senescence; genomic instability feeds the senescent pool (drafted)
telomere-attrition — telomere-associated DDR foci (TAFs) are a dominant source of PDDF in aged post-mitotic and slowly-cycling cells (drafted)
chronic-inflammation — SASP is the primary mechanistic bridge from senescent cells to systemic inflammaging (stub)
deregulated-nutrient-sensing — mTOR drives SASP translation; AMPK-mTOR axis modulates senescence susceptibility (drafted)

Limitations and open questions

gap/needs-human-replication — All genetic lifespan extension data (Baker 2016) are murine. Whether chronic senolytic therapy extends human healthspan or lifespan is unknown. Hickson 2019 / Justice 2019 demonstrate target engagement and preliminary functional signal, but not aging endpoints.
gap/needs-replication — Yousefzadeh 2018 fisetin lifespan data from a single strain and sex; independent replication in genetically heterogeneous mice or NIA ITP is pending.
gap/no-mechanism — The “switch” that determines whether developmental senescence is efficiently cleared vs. chronic accumulation in aged tissue is incompletely characterized at the molecular level. NK-cell and macrophage clearance capacity decline with age, but the rate-limiting molecular determinant is unknown.
gap/contradictory-evidence — IMR90 fibroblast SCAP: Zhu 2016 requires triple BCL-2+BCL-xL+BCL-W for senolysis; Yosef 2016 achieves ~53% viability reduction with BCL-W+BCL-xL dual knockdown alone (different senescence inducers). Senescence-inducer identity modulates SCAP composition — not yet systematically mapped. See senolytics (verified-partial).
gap/long-term-unknown — Chronic senolytic therapy in humans: what is the consequence of long-term, repeated senescent-cell clearance? Wound healing (fibroblast senescence is beneficial transiently), immune responses, and tissue architecture effects have not been studied longitudinally in humans.
gap/unsourced — Osteoarthritis senescent chondrocyte data and therapeutic senolytic trials in OA have been reported (Jeon 2017) but no verified atomic page for osteoarthritis exists yet; links to osteoarthritis (planned stub).
gap/needs-replication — β-cell senescence (Aguayo-Mazzucato 2019) as a T2D driver: PDF not yet verified against full text; see type-2-diabetes (verified, with caveat tag on that claim).
gap/no-mechanism — No biomarker reliably captures the full senescent-cell population across all tissues and inducers. p16INK4a, p21, SA-β-Gal, SASP panel, telomere dysfunction-induced foci (TIF) each capture overlapping but non-identical subsets. A universal, clinically usable senescent-cell biomarker does not exist.

Position in causal hierarchy

This hallmark is classified as Intermediate response/damage tier (mechanistic-tier: intermediate / intervention-tractability: high). See hallmark-causality-graph for the full hierarchy and intervention-sequencing argument.

Direct upstream nodes per caused-by: frontmatter: genomic-instability (DDR → SASP), telomere-attrition (TAFs → replicative senescence), epigenetic-alterations (ICE model; OSK reversal), mitochondrial-dysfunction (MiDAS — disputed direction), deregulated-nutrient-sensing (mTOR drives SASP translation). Direct downstream nodes per causes: frontmatter: chronic-inflammation (SASP → inflammaging), stem-cell-exhaustion (senescent niche cells disrupt HSC/satellite cell niches), altered-intercellular-communication (SASP is the primary paracrine signal disruption in aged tissue). Edge evidence is in causal-graph-data.

doi:10.1073/pnas.92.20.9363 · Dimri GP et al. 1995 · in-vitro + in-vivo (human skin biopsies) · PNAS · SA-β-gal activity established as senescence biomarker; detected in aged human dermis but not young; verified on p21 ↩
doi:10.1038/nature16932 · Baker DJ et al. 2016 · in-vivo (wild-type INK-ATTAC mice; two cohorts: mixed background + C57BL/6J; AP20187 twice weekly from 12 months) · Nature · median lifespan +24–27%; range 17–35% by sex/background; cancer latency increased but incidence not reduced; verified on p21 (verified) and senolytics (verified-partial) ↩ ↩² ↩³ ↩⁴
doi:10.1016/j.ebiom.2019.08.069 · Hickson LJ et al. 2019 · rct-pilot (open-label; n=9; diabetic kidney disease) · EBioMedicine · D 100 mg/day + Q 1,000 mg/day (500 mg ×2) × 3 consecutive days (single course); biopsy at Day 0 and Day 14; p16 −35% (p=0.001), p21 −17% (p=0.009), SA-β-Gal −62% (p=0.005) in adipose biopsies (all = % positive cells, IHC/SA-β-gal counts — NOT mRNA); skin epidermis p16 −20% (p=0.026), p21 −31% (p=0.016); CD68+ macrophages −28% (p<0.0001); circulating SASP factors reduced; first human tissue senescent-cell reduction demonstration; verified on senolytics (verified-partial) ↩ ↩² ↩³
idda-2020-senescent-markers-human-tissues · Idda ML, McClusky WG, Lodde V, Munk R, Abdelmohsen K, Rossi M, Gorospe M · observational (cross-sectional human IHC) · doi:10.18632/aging.102903 · PMID 32160592 · Aging (Albany NY) 2020;12(5):4052–4066 · p16^INK4a^/p21^CIP1^ IHC across 10 organs × 3 age groups (Young 13–35 / Middle 40–59 / Old >65), n=5/organ/group · p16 rises tissue-specifically (endocrine pancreas ~35% in elderly; liver/intestine/spleen/brain p16-only; dermis p21-only; lung no change; skeletal/cardiac muscle undetectable) · model: human autopsy/biopsy tissue arrays · gold OA (PMC7093180) ↩
tuttle-2021-human-senescence-systematic-review · meta-analysis (systematic review) · doi:10.1016/j.arr.2021.101334 · PMID 33819674 · Ageing Research Reviews 2021;68:101334 · 103 studies included (12,590 screened); 9 organ systems, 27 age-related diseases; 27 distinct senescence markers (p16^INK4a^ in 23/27 pathologies); senescence-marker elevation consistently associated with human age-related disease tissue; marker standardization lacking · model: human · gap/no-fulltext-access (abstract-sourced) ↩
krishnamurthy-2004-ink4a-arf-aging-biomarker · doi:10.1172/JCI22475 · PMID 15520862 · Krishnamurthy J et al. (Sharpless lab) · J Clin Invest 2004;114(9):1299–1307 · in-vivo (rodent multi-tissue) · ~9.7-fold geometric-mean p16^INK4a^ rise across 15 murine tissues; CR attenuates; first systematic age-stratified multi-organ survey · bronze OA (PMC524230) ↩ ↩²
ressler-2006-p16-human-skin-biomarker · doi:10.1111/j.1474-9726.2006.00231.x · PMID 16911562 · Ressler S et al. (Jansen-Dürr lab) · Aging Cell 2006;5(5):379–389 · observational (human skin biopsy) · p16^INK4a^ as robust in-vivo biomarker of cellular aging in human skin; BMI1 downregulated with age; Ki67 mutually exclusive with p16 · gap/no-fulltext-access (closed-access; abstract-sourced) ↩
suryadevara-2024-sennet-detection-recommendations · Suryadevara V, Hudgins AD et al.; NIH SenNet Biomarkers Working Group (79 authors) · Nature Reviews Molecular Cell Biology 2024;25(12):1001–1023 · doi:10.1038/s41580-024-00738-8 · PMID 38831121 · review/consensus · per-tissue senescence-detection recommendations across 14 mouse+human tissues (molecular signatures + morphology + circulating markers); no single universal marker · green-OA; abstract-sourced gap/no-fulltext-access ↩
doi:10.1038/ncb1909 · Rodier F et al. (Campisi lab) 2009 · in-vitro (human IMR90 fibroblasts) + ATM/NBS1/CHK2 depletion · Nature Cell Biology · two separable DDR arms — growth arrest (p53/p21) vs SASP (ATM/NBS1/CHK2; p53-independent); verified on dna-damage-response (verified-partial) ↩
suryadevara-2026-senotypes · Suryadevara V et al.; NIH SenNet Consortium; Robbins P, Fan R · review (Perspective) · doi:10.1016/j.cell.2026.05.028 · Cell 189(12):3501–3505 · 2026 Jun 11 · model: human tissue atlas framework · note: paywalled; abstract-sourced only; companion data papers not yet seeded; COI: P. Robbins (Itasca Therapeutics, UMN senotherapeutic patents) ↩
anerillas-2026-sencat · Anerillas C, Altés G, Gresova K et al.; NIH SenNet (NIA IRP; Basisty N, Gorospe M) · Molecular Cell 2026 Jun 11 (online ahead of print) · doi:10.1016/j.molcel.2026.05.017 · PMID 42276073 · multi-omic transcriptome+proteome profiling of 14 primary human cell types × >30 senescence paradigms · no universal marker; shared metabolic + damage-response/repair pathways; ML SenCat signatures for cross-dataset senescence scoring · peer-reviewed; paywalled/abstract-sourced gap/no-fulltext-access ↩
cherqui-2025-senescence-burden-organs · Cherqui U, Sopher I-R, Akiva H et al. (Krizhanovsky lab, Weizmann Institute) · preprint (bioRxiv) · doi:10.1101/2025.11.14.688272 · 2025-11-14 · in-vivo (mouse multi-organ) + human PBMCs · abstract-only; not peer-reviewed · single-cell protein-level multi-marker senescence quantification; intra-organ coordination strong, inter-organ correlation low → tissue-specific aging progression gap/preprint-not-peer-reviewed ↩
freizus-2025-atp6v1b2-persistent-senescence · Freizus N, Majewska JM, Ovadya Y et al. (Krizhanovsky lab, Weizmann Institute) · preprint (bioRxiv) · doi:10.1101/2025.11.30.691415 · 2025-12-01 · in-vitro (human + mouse senescent cells) + in-vivo (aging + fibrotic lungs) · abstract-only; not peer-reviewed · csV1B2-marked senescent subset; apoptosis-resistant; DNA-repair-associated transcriptional signature; ABT-737 resistance correlated with csV1B2 expression gap/preprint-not-peer-reviewed ↩
karin-2019-senescent-cell-turnover-gompertz · Karin O, Agrawal A, Porat Z, Krizhanovsky V, Alon U · Nat Commun 10:5495 (2019) · doi:10.1038/s41467-019-13192-4 · n=33 longitudinal p16-luciferase mice (TBL imaging 8–80 wk) + bleomycin pulse-chase · SnC clearance half-life ~5 d (3 mo) → ~25 d (22 mo); density-dependent self-inhibition (mechanism iv) reproduces the slowdown without invoking extrinsic immune aging; origin of the SR model · model: C57BL/6 mouse · verified against PMC6889273 full text ↩
raz-2026-sr-model-aging-regimes · Raz N et al. · Nat Aging 6:1330–1340 (2026) · doi:10.1038/s43587-026-01138-7 · multi-species SR-model fit; damage-production rate η is the best single lifespan predictor (SHAP 2.85) while removal β is near-invariant across mammals; senescent cells the candidate damage substrate · design: in-silico modeling of observational mortality data ↩
doi:10.1016/j.cell.2017.02.031 · Baar MP et al. 2017 · in-vivo (C57BL/6; XpdTTD/TTD mice; naturally aged mice) + in-vitro (IMR90, WI-38, BJ fibroblasts) · Cell 169:132–147 · FOXO4-DRI peptide disrupts FOXO4-p53 → selective senescent-cell apoptosis; in vivo: plasma urea reduction, improved fur score, physical function, running wheel; local PDF available — verified on foxo4 (verified) ↩ ↩²
doi:10.1111/acel.12344 · Zhu Y et al. (Kirkland lab) 2015 · in-vitro + in-vivo · Aging Cell · SCAP concept established; dasatinib+quercetin as first senolytic combination; cell-type-specific SCAP map; verified on senolytics (verified-partial) ↩ ↩²
doi:10.1016/j.ebiom.2018.12.052 · Justice JN et al. 2019 · rct-pilot (open-label; n=14; IPF patients) · EBioMedicine · D 100 mg + Q 1,250 mg/day × 3 consecutive days/week × 3 weeks (9 dosing days); 6MWT +21.5 m (p=0.012), gait speed +0.12 m/s (p=0.024), chair-stands −2.2 s (p=0.013); pulmonary function NS; verified on senolytics (verified-partial) ↩ ↩²
lombardo-2026-senolytic-demyelination · displayed TEM n=3 mice/age/treatment group; 1,500–2,000 nested axons/group · healthy young and aged mouse + primary rat oligodendrocyte lineage · D+Q-regimen safety signal without brain senolytic target-engagement measurement · doi:10.1073/pnas.2524897123 ↩
doi:10.1073/pnas.1515386112 · Xu M et al. 2015 · in-vivo (aged C57BL/6 mice) · PNAS · JAK1/2 inhibition (momelotinib) reduced SASP markers, improved physical function, grip strength, running; verified on senomorphics (verified-partial) ↩

🧬 Aging Wiki

Explorer

cellular-senescence

Cellular Senescence

Definition (López-Otín 2013, retained 2023)

Discovery: the Hayflick limit and modern senescence biology

Triggers of senescence

1. DNA damage / replicative senescence

2. Oncogene-induced senescence (OIS)

3. Stress-induced premature senescence (SIPS)

4. Developmental / transient senescence

5. Mitochondrial dysfunction-induced senescence (MiDAS)

6. Mitochondrial RNA leakage as DAMP-driven SASP amplifier

Senescent-cell heterogeneity and the senotype concept

Two arms of intervention: production rate and clearance

Core molecular machinery

p53/p21 growth-arrest axis

p16INK4a/Rb axis — reinforcement layer

SASP: the secretory output

Anti-apoptotic programs (SCAPs)

Genetic proof: lifespan extension by senescent-cell clearance

Senolytic intervention paradigm

Senomorphic intervention paradigm

Aging-cancer paradox

Disease phenotype cluster

Clinical translation

Human senescent-cell burden evidence

Active human trials (as of 2026)

Translation caveats

Targeted interventions

Cross-references

Limitations and open questions

See also

Position in causal hierarchy

Graph View

Table of Contents

Backlinks

🧬 Aging Wiki

Explorer

cellular-senescence

Cellular Senescence

Definition (López-Otín 2013, retained 2023)

Discovery: the Hayflick limit and modern senescence biology

Triggers of senescence

1. DNA damage / replicative senescence

2. Oncogene-induced senescence (OIS)

3. Stress-induced premature senescence (SIPS)

4. Developmental / transient senescence

5. Mitochondrial dysfunction-induced senescence (MiDAS)

6. Mitochondrial RNA leakage as DAMP-driven SASP amplifier

Senescent-cell heterogeneity and the senotype concept

Two arms of intervention: production rate and clearance

Core molecular machinery

p53/p21 growth-arrest axis

p16INK4a/Rb axis — reinforcement layer

SASP: the secretory output

Anti-apoptotic programs (SCAPs)

Genetic proof: lifespan extension by senescent-cell clearance

Senolytic intervention paradigm

Senomorphic intervention paradigm

Aging-cancer paradox

Disease phenotype cluster

Clinical translation

Human senescent-cell burden evidence

Active human trials (as of 2026)

Translation caveats

Targeted interventions

Cross-references

Limitations and open questions

See also

Position in causal hierarchy

Footnotes

Graph View

Table of Contents

Backlinks